BRD1991
CAS No.
BRD1991 ( BRD-1991 )
Catalog No. M17099 CAS No.
BRD1991 is a small molecule that selectively disrupt Beclin 1/Bcl-2 binding as compared to Bax/Bcl-2 and Bim/Bcl-2 binding and induces autophagic flux at concentrations with minimal cytotoxicity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
100MG | Get Quote | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBRD1991
-
NoteResearch use only, not for human use.
-
Brief DescriptionBRD1991 is a small molecule that selectively disrupt Beclin 1/Bcl-2 binding as compared to Bax/Bcl-2 and Bim/Bcl-2 binding and induces autophagic flux at concentrations with minimal cytotoxicity.
-
DescriptionBRD1991 is a small molecule that selectively disrupt Beclin 1/Bcl-2 binding as compared to Bax/Bcl-2 and Bim/Bcl-2 binding and induces autophagic flux at concentrations with minimal cytotoxicity.
-
SynonymsBRD-1991
-
PathwayAngiogenesis
-
TargetBcl-2
-
RecptorBcl-2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number--
-
Formula Weight608.56
-
Molecular FormulaC33H35Cl2N3O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name3,5-dichloro-N-((10-(1-hydroxypropan-2-yl)-8,12-dimethyl-11-oxo-7,8,9,10,11,12-hexahydro-5H-benzo[9,10][1]oxa[5]azacycloundecino[7,8-b]indol-7-yl)methyl)-N-methylbenzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Chiang WC, et al. ACS Chem Biol. 2018 Jun 21. doi: 10.1021/acschembio.8b00421.
molnova catalog
related products
-
CYD-2-11
CYD-2-11 is a novel potent, selective Bax agonist that targets the structural pocket proximal to S184 in the C-terminal region of Bax (Ki=34.1 nM).
-
A-1331852
A-1331852 is a potent and selective BCL-XL inhibitor (Ki<10 pM); shows much weaker affinity for BCL-2 (Ki=6 nM), BCL-W (Ki=4 nM), and MCL-1 (Ki=142 nM).
-
BXI-72
BXI-72 (NSC334072, Hoechst 33342) is a potent, selective small molecule Bcl-XL inhibitor that targets the BH3 domain of Bcl-XL (Kd=0.9 nM).